BI-Lupin Deal To Up The Heat In Indian DPP-4 Market
This article was originally published in Scrip
Innovator firms continue to tap into the marketing muscle of domestic companies as they vie for a bigger share of India's highly competitive dipeptidyl peptidase-4 (DPP-4) inhibitor market.
You may also be interested in...
More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.